1. Home
  2. TNXP

TNXP

Tonix Pharmaceuticals Holding Corp.

Logo Tonix Pharmaceuticals Holding Corp.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Founded: 2007 Country:
United States
United States
Employees: N/A City: CHATHAM
Market Cap: 14.4M IPO Year: N/A
Target Price: $5.50 AVG Volume (30 days): 2.0M
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -6.85 EPS Growth: N/A
52 Week Low/High: $0.16 - $3.44 Next Earning Date: 05-06-2024
Revenue: $7,768,000 Revenue Growth: N/A
Revenue Growth (this year): 120.16% Revenue Growth (next year): 46.12%

Share on Social Networks: